-
TherapeutAix to present at the Anti-Fibrotic Drug Development Summit in Boston
We are proud partners for the 3rd Annual Anti-Fibrotic Drug Development Summit (AFDD) which will take place on November 18-20th…
0 -
TherapeutAix to present at ELRIG Drug Discovery 2019 in Liverpool
Now in its 13th year, Drug Discovery 2019, ELRIG’s flagship conference, will take place at the ACC in Liverpool on…
-
TherapeutAix to attend the ERS International Congress 2019 in Madrid
The annual ERS International Congress welcomes over 20,000 delegates each year and showcases excellence across the field of respiratory medicine.…
-
Drug Development in IPF – An Open Innovation Workshop
From the inception of TherapeutAix, a key aim has been to bring decision-making information within reach of smaller organisations. Frequently…
-
One year round up – what we’ve been up to in our first year
The 1st September 2019 officially marks the one year anniversary of the launch of TherapeutAix – and what an exciting…
-
TherapeutAix to attend the ‘New Targets & Modalities in Fibrosis’ ELRIG Networking event on the 18th September
Held in Oxford on September 18th, this ELRIG event will look at what researchers are doing to support patients with…
-
International NASH Day 2019
On International NASH Day 2019 we discuss the mixed outcomes of NASH drug clinical trials and how we believe a…
-
TherapeutAix adds Immunoconsulting to global R&D Network
We are pleased to announce that we have grown our global R&D Network with the addition of ImmunoConsulting Ltd. ImmunoConsulting,…
-
Recent study highlights the challenges in developing treatments for NASH
We previously commented on the failure of the ASK-1 inhibitor, selonsertib, in the STELLAR-4 phase III study in patients with compensated…
-
TherapeutAix/Medicines Discovery Catapult session on drug discovery in fibrotic disease at the BOS Basel event in Switzerland
BOS (Biotech Outsourcing Strategies) Basel 2019 will bring together stakeholders in pharmaceutical R&D outsourcing, who share knowledge, develop skills and…
